TNFRSF10B and neoplasm: In this study, we investigated the enhanced anti-tumor activity of the death agonist antibody against TRAILR2/DR5 plus TRAIL when combined with the SMAC mimetic IAP inhibitor birinapant in HPV(+) HNSCC cells.